Chemomab Therapeutics Ltd.
CMMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $32 | $6 | $36 | $72 |
| - Cash | $6 | $9 | $14 | $15 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $27 | -$3 | $23 | $57 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$14 | -$25 | -$28 | -$12 |
| % Margin | – | – | – | – |
| Net Income | -$14 | -$24 | -$28 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.12 | -8.22 | -9.68 | -4.8 |
| % Growth | 62% | 15.1% | -101.7% | – |
| Operating Cash Flow | -$15 | -$24 | -$20 | -$12 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$15 | -$24 | -$20 | -$13 |